

Title: New Triptan drugs formulations and administration ways in migraine patients

Name: Keishid ABTAHI
Eastern Mediterranean University-Faculty of Pharmacy, Famagusta Cyprus

In last years of migraine treatment research one of the most anticipated drugs are Triptans, they are a family of tryptamine-based drugs used as abortive medication in the treatment of migraines and cluster headaches. This drug class was first introduced in the 1990s. Since introduction scientists are working on different administration ways for this medication. One of the latest FDA approved administrations is nasal spray formulation for Sumatriptan under the brand name of Tosymra® which can be used to treat migraine attacks and it shows the effect in 15 minutes.
Nasal triptans (sumatriptan and zolmitriptan) contain migraine-specific treatment. Triptans are highly effective but do cause blood vessel narrowing and should not be used in people with known or suspected vascular disease. How was it developed and mechanism of action will be discussed during presentation in 18th International Conference on Pharmaceutics & Novel Drug Delivery Systems.

Biography

Keishid ABTAHI has completed his Pharm.D at the age of 25 years from Eastern Mediterranean University and he is nominated as PhD student in Başkent University starting in September 2019. He is an IPSF (International Pharmacy Students Federation) soft skills trainer and he is the first of this group in Iran, Turkey and Cyprus. He was the president of EMU Pharmacy Students Society and also, he had the chance to work as chairperson of 2nd international EMU pharmacy congress held in Famagusta-Cyprus in 2016.

Presenting author details

Full name: Keishid ABTAHI
Contact number: +98 935 519 3555 / +90 533 843 0044
Linked In account: https://www.linkedin.com/in/keishid-abtahi/
Session name/ number: New Triptan drugs formulations and administration ways in migraine patients
Category: (Oral presentation)